Pharvaris N.V. (PHVS) Discusses Topline Data From RAPIDe-3 Phase III Study of Deucrictibant for Hereditary Angioedema Transcript

December 03, 2025 05:43:24 pm

Source: SeekingAlpha

2025-12-03 17:43:24 ET

Pharvaris N.V. (PHVS) Discusses Topline Data From RAPIDe-3 Phase III Study of Deucrictibant for Hereditary Angioedema December 3, 2025 8:00 AM EST...

For further details see:

Pharvaris N.V.

2.75% G/L:

$28 Last:

17,480 Volume:

$27.56 Open:

February 10, 2026 06:50:00 am

January 12, 2026 06:50:00 am

December 03, 2025 08:06:29 pm

December 03, 2025 07:15:03 pm

Market Cap $1,492,567,159

Float 37,790,994

Insiders Ownership N/A

Institutions 37

Short Percent N/A

Industry Biotechnology & Life Sciences

Sector Healthcare

Country NL

City Leiden